Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
MONDO:0006115An advanced phase of chronic myelogenous leukemia. It is characterized by: 1. the presence of blasts in the peripheral blood or bone marrow that are at least 20% of the peripheral blood white cells or of the nucleated cells in the bone marrow respectively, or 2. an extramedullary proliferation of blasts, and/or 3. when there are large aggregates and clusters of blasts in the bone marrow biopsy specimen (adapted from WHO, 2001).
Also known as: blast crisis, blast phase CML, blast phase chronic granulocytic leukaemia, blast phase chronic granulocytic leukemia, blast phase chronic myelocytic leukaemia, blast phase chronic myelocytic leukemia, blast phase chronic myelogenous leukaemia, blast phase chronic myelogenous leukemia
3128 clinical trials for this condition and its sub-types, 64 tagged with Blast phase chronic myelogenous leukemia, BCR-ABL1 positive itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Drug cocktail aims to tame advanced leukemia
Disease control CompletedThis phase 2 trial is testing whether combining two drugs, ponatinib and 5-azacitidine, can improve survival in people with advanced chronic myeloid leukemia (CML). The study includes adults whose CML has progressed to an accelerated phase or a more aggressive blast crisis. Parti…
Phase 2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Experimental drug RAD001 tested for tough leukemias and lymphomas
Disease control CompletedThis study tested the drug RAD001 (everolimus) in 29 patients with relapsed or hard-to-treat blood cancers like leukemia, lymphoma, and myelofibrosis. The goal was to find the safest highest dose and see if it helps control the disease. It was a small early-phase trial at a singl…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail shows promise against tough leukemia
Disease control CompletedThis study tested a combination of three drugs (decitabine, venetoclax, and ponatinib) in 20 adults with a rare, aggressive leukemia called Philadelphia chromosome-positive acute myeloid leukemia or chronic myelogenous leukemia in blast phase. The goal was to see if the drugs cou…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo shrinks spleens in bone marrow cancer patients
Disease control CompletedThis study tested a new drug called pelabresib in people with certain blood cancers, including myelofibrosis and leukemia. In the first part, the drug was given alone to find the safest dose. In the second part, it was given with or without another drug (ruxolitinib) to see if it…
Phase 1/2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Intense Pre-Transplant combo shows promise for tough leukemias
Disease control CompletedThis phase 2 trial tested a combination of intravenous busulfan, etoposide, and low-dose total-body irradiation before a donor stem cell or bone marrow transplant in 30 patients with advanced leukemia or myelodysplastic syndromes. The goal was to see how well this regimen control…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Selective immune cell removal may tame transplant complications
Disease control CompletedThis study tested whether removing a specific type of immune cell (naïve T cells) from donor stem cell grafts could prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. The trial enrolled 84 patients who received high- or medium-intensity chemo…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Expanded cord blood transplant shows early promise for young cancer patients
Disease control CompletedThis study tested a new method of cord blood transplantation in 13 children and young adults with high-risk myeloid cancers. The approach uses a molecule called UM171 to grow more stem cells from a single cord blood unit, aiming to speed up recovery and reduce complications. Earl…
Phase 1/2 • Sponsor: ExCellThera inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Cord blood boost: new technique shows promise for tough leukemia cases
Disease control CompletedThis study tested a new way to prepare cord blood for transplant in 30 people with high-risk leukemia or myelodysplasia. The cord blood was treated with a molecule called UM171 to help it grow more stem cells. The goal was to see if this approach is safe and helps patients recove…
Phase 2 • Sponsor: ExCellThera inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for CML patients: dasatinib shows promise in early treatment
Disease control CompletedThis study tested whether the drug dasatinib can control chronic myeloid leukemia (CML) in its early chronic phase. 150 adults with newly diagnosed CML took dasatinib, and researchers measured how many achieved a major molecular response (very low levels of cancer genes) after 12…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug combo may reduce chronic transplant complications in blood cancer patients
Disease control CompletedThis study tested whether a combination of two drugs, cyclophosphamide and abatacept, could lower the risk of chronic graft-versus-host disease (GVHD) after a stem cell transplant in people with high-risk blood cancers. GVHD happens when donor cells attack the patient's body. The…
Phase 2 • Sponsor: Dimitrios Tzachanis, MD PhD • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC